Biogen Inc (BIIB) is a Healthcare · Drug Manufacturers - General company listed on NASDAQ. Price $217.34 (-0.78%), Market cap $27.97B, P/E ratio 20.37, 52-week low–high $122.68 ~ $204.53.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat no
Financial statements, price targets, institutional (13F) holdings and related news for Biogen Inc are updated in real time on BlackAll Trade.
Biogen Inc trades at $217.34 (-0.78%). Real-time quotes and charts are available on BlackAll Trade.
Biogen Inc has a market cap of about $27.97B. Its P/E ratio is 20.37.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and